Who we are?

We are committed to discovering, developing and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. Led by a world-class management team of seasoned industry executives, we have built a fully integrated biopharmaceutical platform with strong in-house R&D capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, and commercialization.

Our Pipeline

We focus on the discovery and development of innovative medicines to address significant unmet medical needs of diseases that are specially prevalence in Chinese population.

Dedicated and Deliver

We have built a fully integrated biopharmaceutical platform that allows us to oversee all aspects of the drug development cycle. By having all functions in-house, we are able to improve operational efficiency and control quality every step of the way.

Company News
03/12/2021

InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List

15/11/2021

InnoCare Announces the Clearance of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 by U.S. FDA

12/11/2021

InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development